TEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation

TEA domain family members (TEADs) play important roles in tumor progression. Till now, the genomic status of TEADs in patients with glioma has not been well investigated. To confirm whether the genomic status of TEADs could affect the prognosis of patients with glioma, the copy number variation (CNV...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuan Hai-Yan, Lv Ya-Juan, Chen Yi, Li Dan, Li Xi, Qu Jian, Yan Han
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	low-grade glioma copy number variation tead4 prognosis gene expression Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/8248fefa47e746918e40eb24a24d31e7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8248fefa47e746918e40eb24a24d31e7
record_format	dspace
spelling	oai:doaj.org-article:8248fefa47e746918e40eb24a24d31e72021-12-05T14:10:41ZTEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation2391-541210.1515/biol-2021-0039https://doaj.org/article/8248fefa47e746918e40eb24a24d31e72021-04-01T00:00:00Zhttps://doi.org/10.1515/biol-2021-0039https://doaj.org/toc/2391-5412TEA domain family members (TEADs) play important roles in tumor progression. Till now, the genomic status of TEADs in patients with glioma has not been well investigated. To confirm whether the genomic status of TEADs could affect the prognosis of patients with glioma, the copy number variation (CNV), mutation and expression data of glioma cohorts in The Cancer Genome Atlas, Gene Expression Omnibus and Chinese Glioma Genome Atlas were comprehensively analyzed. Results showed that TEAD CNV frequency in lower grade gliomas (LGGs) was higher than in glioblastoma multiforme (GBM). Multivariate cox regression analysis showed that TEAD4 CNV increase was significantly associated with overall survival (OS) and disease-free survival (DFS) in LGGs (OS p = 0.022, HR = 1.444, 95% CI: 1.054–1.978; DFS p = 0.005, HR = 1.485, 95% CI: 1.124–1.962), while not in GBM. Patients with TEAD4 CNV increase showed higher expression level of TEAD4 gene. In LGG patients with IDH mutation, those with higher TEAD4 expression levels had shorter OS and DFS. Integrating TEAD4 CNV increase, IDH mutations, TP53 mutation, ATRX mutation and 1p19q co-deletion would separate patients with LGG into four groups with significant differences in prognosis. These study results suggested that TEAD4 variations were independent predictive biomarkers for the prognosis in patients with LGG with IDH mutation.Yuan Hai-YanLv Ya-JuanChen YiLi DanLi XiQu JianYan HanDe Gruyterarticlelow-grade gliomacopy number variationtead4prognosisgene expressionBiology (General)QH301-705.5ENOpen Life Sciences, Vol 16, Iss 1, Pp 323-335 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	low-grade glioma copy number variation tead4 prognosis gene expression Biology (General) QH301-705.5
spellingShingle	low-grade glioma copy number variation tead4 prognosis gene expression Biology (General) QH301-705.5 Yuan Hai-Yan Lv Ya-Juan Chen Yi Li Dan Li Xi Qu Jian Yan Han TEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation
description	TEA domain family members (TEADs) play important roles in tumor progression. Till now, the genomic status of TEADs in patients with glioma has not been well investigated. To confirm whether the genomic status of TEADs could affect the prognosis of patients with glioma, the copy number variation (CNV), mutation and expression data of glioma cohorts in The Cancer Genome Atlas, Gene Expression Omnibus and Chinese Glioma Genome Atlas were comprehensively analyzed. Results showed that TEAD CNV frequency in lower grade gliomas (LGGs) was higher than in glioblastoma multiforme (GBM). Multivariate cox regression analysis showed that TEAD4 CNV increase was significantly associated with overall survival (OS) and disease-free survival (DFS) in LGGs (OS p = 0.022, HR = 1.444, 95% CI: 1.054–1.978; DFS p = 0.005, HR = 1.485, 95% CI: 1.124–1.962), while not in GBM. Patients with TEAD4 CNV increase showed higher expression level of TEAD4 gene. In LGG patients with IDH mutation, those with higher TEAD4 expression levels had shorter OS and DFS. Integrating TEAD4 CNV increase, IDH mutations, TP53 mutation, ATRX mutation and 1p19q co-deletion would separate patients with LGG into four groups with significant differences in prognosis. These study results suggested that TEAD4 variations were independent predictive biomarkers for the prognosis in patients with LGG with IDH mutation.
format	article
author	Yuan Hai-Yan Lv Ya-Juan Chen Yi Li Dan Li Xi Qu Jian Yan Han
author_facet	Yuan Hai-Yan Lv Ya-Juan Chen Yi Li Dan Li Xi Qu Jian Yan Han
author_sort	Yuan Hai-Yan
title	TEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation
title_short	TEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation
title_full	TEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation
title_fullStr	TEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation
title_full_unstemmed	TEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation
title_sort	tead4 is a novel independent predictor of prognosis in lgg patients with idh mutation
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/8248fefa47e746918e40eb24a24d31e7
work_keys_str_mv	AT yuanhaiyan tead4isanovelindependentpredictorofprognosisinlggpatientswithidhmutation AT lvyajuan tead4isanovelindependentpredictorofprognosisinlggpatientswithidhmutation AT chenyi tead4isanovelindependentpredictorofprognosisinlggpatientswithidhmutation AT lidan tead4isanovelindependentpredictorofprognosisinlggpatientswithidhmutation AT lixi tead4isanovelindependentpredictorofprognosisinlggpatientswithidhmutation AT qujian tead4isanovelindependentpredictorofprognosisinlggpatientswithidhmutation AT yanhan tead4isanovelindependentpredictorofprognosisinlggpatientswithidhmutation
_version_	1718371849185787904

TEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation

Ejemplares similares